CurrentEndo
Get Weekly

CurrentEndo coverage · page 25 of 55

Diabetes, Obesity and Metabolism

Briefs 961–1,000 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial

    Secondary analysisComplications

  2. Diabetes Obes Metab

    Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials

    Meta-analysisTechnology

  3. Diabetes Obes Metab

    Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection

    Cohort studyT2D & other

  4. Diabetes Obes Metab

    Iodine uptake variability as a predictive biomarker for radioiodine therapy outcomes in Graves Disease: Validation through multi‐time‐point RAIU assessment in a 1249‐patient cohort

    Cohort studyThyroid

  5. Diabetes Obes Metab

    Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study

    Cohort studyObesity

  6. Diabetes Obes Metab

    HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis

    Randomized controlled trialT2D & other

  7. Diabetes Obes Metab

    The impact of plasma glucose decline rate on cardiac repolarisation in individuals with type 1 diabetes

    Randomized controlled trialT1D

  8. Diabetes Obes Metab

    Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes

    Research articleT2D & other

  9. Diabetes Obes Metab

    Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes

    Cohort studyLipids & liver

  10. Diabetes Obes Metab

    Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes

    Cohort studyT2D & other

  11. Diabetes Obes Metab

    Menopause factors and alterations in gut microbiota and insulin homeostasis: A cross‐sectional analysis of the microbiome and insulin longitudinal evaluation study ( MILES )

    Cross-sectional studyReproductive endocrine

  12. Diabetes Obes Metab

    The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes—rationale and protocol of the prospective, randomized, open‐labelled multicentre study

    Trial designT1D

  13. Diabetes Obes Metab

    Decreases in circulating ANGPTL3 /8 concentrations following retatrutide treatment parallel reductions in serum lipids

    Secondary analysisT2D & other

  14. Diabetes Obes Metab

    Evaluating biased agonism of glucagon‐like peptide‐1 ( GLP ‐1) receptors to improve cellular bioenergetics: A systematic review

    Meta-analysisT2D & other

  15. Diabetes Obes Metab

    Lack of evidence for obesity paradox in patients with cardiovascular disease: A UK BioBank cohort study

    Cohort studyObesity

  16. Diabetes Obes Metab

    Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52‐week, multicentre, randomized, placebo‐controlled, phase III clinical trial

    Randomized controlled trialT2D & other

  17. Diabetes Obes Metab

    Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals

    Cross-sectional studyObesity

  18. Diabetes Obes Metab

    Differential effects of lifestyle interventions on continuous glucose monitoring metrics in persons with type 2 diabetes: Potential for personalised treatment

    Research articleTechnology

  19. Diabetes Obes Metab

    Diabetes is one of the main drivers of mortality in Mexico: A latent class analysis of chronic diseases using the Mexico City Prospective Study

    Cohort studyT2D & other

  20. Diabetes Obes Metab

    Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study

    Cross-sectional studyT1D

  21. Diabetes Obes Metab

    Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6

    Secondary analysisT2D & other

  22. Diabetes Obes Metab

    Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial

    Secondary analysisT2D & other

  23. Diabetes Obes Metab

    Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide

    Secondary analysisT2D & other

  24. Diabetes Obes Metab

    The association between inflammation and glucose levels in hospitalised patients with type 2 diabetes

    Secondary analysisT2D & other

  25. Diabetes Obes Metab

    Exploring the value of ChatGPT in selecting antidiabetic agents for type 2 diabetes

    Cohort studyT2D & other

  26. Diabetes Obes Metab

    Overweight, obesity and incident atrial fibrillation: Real‐world evidence from 400 000 patients in Germany

    Cohort studyObesity

  27. Diabetes Obes Metab

    Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021

    Cohort studyComplications

  28. Diabetes Obes Metab

    N‐lactoyl amino acids are potential biomarkers for insulin resistance and diabetic complications

    Cross-sectional studyT2D & other

  29. Diabetes Obes Metab

    Large‐scale web‐based survey on eating behaviour in the Japanese general population using a dietary behaviour questionnaire

    Cross-sectional studyObesity

  30. Diabetes Obes Metab

    Effects of reducing sedentary behaviour on renal glucose uptake during insulin stimulation: A post‐hoc analysis of a 6‐month randomized controlled trial

    Secondary analysisObesity

  31. Diabetes Obes Metab

    A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada

    Cohort studyObesity

  32. Diabetes Obes Metab

    Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta‐analysis

    Meta-analysisT2D & other

  33. Diabetes Obes Metab

    Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss

    Diagnostic or prognostic studyObesity

  34. Diabetes Obes Metab

    Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study

    Diagnostic or prognostic studyT2D & other

  35. Diabetes Obes Metab

    Cognitive reserve, genetic risk, and lifestyle in the incidence and progression of type 2 diabetes: A large community‐based longitudinal study

    Cohort studyT2D & other

  36. Diabetes Obes Metab

    Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1

    Secondary analysisObesity

  37. Diabetes Obes Metab

    Adherence to four dietary indices and the risk of all‐cause and cause‐specific dementia: Findings from the UK Biobank study

    Cohort study

  38. Diabetes Obes Metab

    Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes

    Cross-sectional studyT2D & other

  39. Diabetes Obes Metab

    Cardiometabolic diseases and dynamic transitions of neuropsychiatric disorders: A longitudinal trajectory analysis

    Cohort studyT2D & other

  40. Diabetes Obes Metab

    Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset

    Cohort studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 961–1,000 of 2,200, newest first